Table 2.
Regression models examining predictors of rheumatoid arthritis treatment initiation of tsDMARD (JAKi) or switch to tsDMARD from bDMARD.
| Treatment initiation with JAKi vs. bDMARDs (logistic regression) Odds ratio (95%CI) |
Treatment switch to JAKi from bDMARD (Cox proportional hazards) Hazard ratio (95%CI) |
|||
|---|---|---|---|---|
| Independent variables | Univariate | Multivariate | Univariate | Multivariate |
| Female | 1.10 (0.95; 1.28) | 1.09 (0.94; 1.27) | 0.98 (0.88; 1.08) | 0.99 (0.90; 1.10) |
| > 50 years at first RA ICD claim | 1.73 (1.53; 1.95) | 1.78 (1.57; 2.01) | 1.20 (1.12; 1.28) | 1.08 (1.01; 1.16) |
| SUS-exclusive status | 0.55 (0.5; 0.62) | 0.53 (0.47; 0.59) | 1.06 (0.99; 1.13) | 1.10 (1.03; 1.18 |
| Distance > 160 km residence to clinic | 0.55 (0.44; 0.69) | 0.57 (0.45; 0.72) | 1.21 (1.06; 1.39) | 1.18 (1.03; 1.35) |
| Time from first RA claim to first b/tsDMARD treatment—months | 1.02 (1.01; 1.03) | 1.01 (0.99; 1.02) | 1.02 (1.02; 1.02) | 1.01 (1.01; 1.01) |
| Number of prior bDMARD used | – | – | 0.15 (0.14; 0.16) | 0.15 (0.14; 0.16) |
| Number of prior csDMARD used | 1.21 (1.11; 1.31) | 1.23 (1.08; 1.41) | 1.35 (1.31; 1.4) | 1.16 (1.11; 1.22) |
DMARD disease modifying antirheumatic drug, JAKi Janus kinase inhibitor, b/tsDMARD biologic/targeted synthetic/tofacitinib (JAKi) DMARD drug, cDMARD conventional DMARD, CI confidence interval, N number of patients, ICD International Classification of Disease, SUS Sistema Único de Saúde, SUS-exclusive dependent on SUS for all healthcare resources, SUS+ private only dependent on SUS for prescription drug coverage.
Distance residence to clinic: distance was calculated as the Euclidean distance (km) between two postal codes: patient’s residence and the healthcare facility/institution. Cox ratio determines the switching pattern of bDMARD to JAKi and odds ratio determine the initiating rates of JAKi.